select a format

Single User License
USD 1500 INR 96555
Site License
USD 3000 INR 193110
Corporate User License
USD 4500 INR 289665

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Lupin Limited-Product Pipeline Review-2015

Lupin Limited-Product Pipeline Review-2015


  • Products Id :- GMDHC07267CDB
  • |
  • Pages: 43
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Lupin Limited-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Lupin Limited-Product Pipeline Review-2015', provides an overview of the Lupin Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lupin Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Lupin Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Lupin Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Lupin Limited's pipeline products

Reasons To Buy

Evaluate Lupin Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Lupin Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Lupin Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Lupin Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lupin Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Lupin Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Lupin Limited Snapshot 6

Lupin Limited Overview 6

Key Information 6

Key Facts 6

Lupin Limited-Research and Development Overview 7

Key Therapeutic Areas 7

Lupin Limited-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Lupin Limited-Pipeline Products Glance 12

Lupin Limited-Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Lupin Limited-Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Lupin Limited-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Lupin Limited-Unknown Stage Pipeline Products 17

Unknown Products/Combination Treatment Modalities 17

Lupin Limited-Drug Profiles 18

Biosimilar for Cancer 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

LND-101001 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LNP-1892 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Biosimilar for Inflammation 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Biosimilar for Ophthalmology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Biosimilar for Osteoporosis 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Biosimilar for Viral Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

etanercept biosimilar 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecule for Autoimmune Diseases 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule for Pain and Inflammation 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Viral Infections 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule for Cancer 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule for Endocrine Disorders 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Lupin Limited-Pipeline Analysis 31

Lupin Limited-Pipeline Products by Target 31

Lupin Limited-Pipeline Products by Route of Administration 32

Lupin Limited-Pipeline Products by Molecule Type 33

Lupin Limited-Pipeline Products by Mechanism of Action 34

Lupin Limited-Recent Pipeline Updates 35

Lupin Limited-Dormant Projects 36

Lupin Limited-Company Statement 37

Lupin Limited-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

Lupin Limited, Key Information 6

Lupin Limited, Key Facts 6

Lupin Limited-Pipeline by Indication, 2015 9

Lupin Limited-Pipeline by Stage of Development, 2015 10

Lupin Limited-Monotherapy Products in Pipeline, 2015 11

Lupin Limited-Phase III, 2015 12

Lupin Limited-Phase II, 2015 13

Lupin Limited-Phase I, 2015 14

Lupin Limited-Preclinical, 2015 15

Lupin Limited-Discovery, 2015 16

Lupin Limited-Unknown, 2015 17

Lupin Limited-Pipeline by Target, 2015 31

Lupin Limited-Pipeline by Route of Administration, 2015 32

Lupin Limited-Pipeline by Molecule Type, 2015 33

Lupin Limited-Pipeline Products by Mechanism of Action, 2015 34

Lupin Limited-Recent Pipeline Updates, 2015 35

Lupin Limited-Dormant Developmental Projects,2015 36

Lupin Limited, Other Locations 38

Lupin Limited, Subsidiaries 39

List of Figures

Lupin Limited-Pipeline by Top 10 Indication, 2015 8

Lupin Limited-Pipeline by Stage of Development, 2015 10

Lupin Limited-Monotherapy Products in Pipeline, 2015 11

Lupin Limited-Pipeline by Top 10 Route of Administration, 2015 32

Lupin Limited-Pipeline by Top 10 Molecule Type, 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Lupin Limited; Lupin Limited - Key Therapeutics; Lupin Limited - Pipeline Overview and Promising Molecules; Lupin Limited - News; Lupin Limited - Latest Updates; Lupin Limited - Pipeline; Lupin Limited - Discontinued/Dormant Projects


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com